Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited.MethodThis multicenter retrosp...

Full description

Bibliographic Details

Published in:	Frontiers in Medicine
Main Authors:	Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Antonio Cristaudo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Francesca M. Gaiani, Paolo Gisondi, Alessandro Giunta, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Annamaria Offidani, Diego Orsini, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Piergiorgio Malagoli, Antonio Costanzo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Subjects:	biologics bimekizumab psoriasis psoriasis treatment real-life
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1243843/full